ACLXArcellx, Inc.

$7B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$108M-2.2% YoY

Gross Profit

$103M95.2% margin

Operating Income

-$138M-127.5% margin

Net Income

-$107M-99.5% margin

EPS (Diluted)

$-2.00

Cash Flow

Operating Cash Flow

-$83M

Free Cash Flow

-$97M

Stock-Based Comp.

$61M

Balance Sheet

Total Assets

$711M

Total Liabilities

$257M

Stockholders' Equity

$455M

Cash & Equivalents

$106M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$108M	$110M	-2.2%
Gross Profit	$103M	$110M	-6.9%
Operating Income	-$138M	-$90M	-53.1%
Net Income	-$107M	-$71M	-51.9%

ACLX FY 2024 Earnings — Arcellx, Inc. Revenue & Financial Results | Market Cap Arena